Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiorenal risk: an important clinical intersection.

Peter A McCullough1

  • 1Section of Cardiology, Departments of Basic Science and Internal Medicine, University of Missouri-Kansas City School of Medicine, Truman Medical Center, Kansas City, MO, USA.

Reviews in Cardiovascular Medicine
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating plasma dipeptidyl dipeptidase 3 and the prognosis of cardiogenic shock.

European journal of heart failure·2019
Same author

The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.

Cardiorenal medicine·2019
Same author

The Promise of next generation sequencing micro RNA for the discovery of new targets in contrast induced acute kidney injury.

Annals of translational medicine·2019
Same author

Doppler-Derived Renal Venous Stasis Index in the Prognosis of Right Heart Failure.

Journal of the American Heart Association·2019
Same author

Serial Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 and the Prognosis for Acute Kidney Injury over the Course of Critical Illness.

Cardiorenal medicine·2019
Same author

Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization - a Review.

Reviews in cardiovascular medicine·2019

Millions of Americans face combined chronic cardiovascular and kidney disease. Renin-angiotensin system antagonism shows promise in protecting both heart and kidney health, reducing disease progression and major endpoints.

Area of Science:

  • Cardiorenal Medicine
  • Nephrology
  • Cardiology

Background:

  • Cardiovascular and kidney diseases frequently coexist, affecting millions and presenting complex clinical challenges.
  • Patients with chronic kidney disease (CKD) face significantly elevated risks for cardiovascular events, including atherosclerosis, myocardial infarction, heart failure, arrhythmias, and cardiac death.
  • CKD complicates the use of standard cardioprotective treatments, necessitating specialized therapeutic approaches.

Purpose of the Study:

  • To explore the intricate relationship between cardiovascular and kidney diseases.
  • To highlight novel diagnostic and therapeutic strategies for patients with cardiorenal conditions.
  • To emphasize the benefits of targeting the cardiorenal intersection.

Main Methods:

Related Experiment Videos

  • Review of observational studies quantifying acute renal failure risk in interventional procedures.
  • Analysis of evidence supporting therapeutic interventions for cardiorenal disease.
  • Focus on renin-angiotensin system antagonism as a dual-acting therapy.

    • Main Results:

    • While procedural risks are low for the general cardiovascular population, CKD significantly elevates cardiovascular event risk.
    • Renin-angiotensin system antagonism demonstrates potential in slowing disease progression and preventing adverse cardiac and renal outcomes.
    • Innovative diagnostic and therapeutic strategies are emerging for this high-risk group.

    Conclusions:

    • The cardiorenal intersection poses significant risks and challenges, requiring focused clinical attention.
    • Therapies targeting both the heart and kidneys, such as renin-angiotensin system antagonism, offer a promising approach to improve patient outcomes.
    • Continued research into innovative strategies is crucial for managing combined cardiovascular and kidney disease.